337 related articles for article (PubMed ID: 34203247)
1. The V-ATPase
Chu A; Zirngibl RA; Manolson MF
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203247
[TBL] [Abstract][Full Text] [Related]
2. Novel c.G630A TCIRG1 mutation causes aberrant splicing resulting in an unusually mild form of autosomal recessive osteopetrosis.
Zirngibl RA; Wang A; Yao Y; Manolson MF; Krueger J; Dupuis L; Mendoza-Londono R; Voronov I
J Cell Biochem; 2019 Oct; 120(10):17180-17193. PubMed ID: 31111556
[TBL] [Abstract][Full Text] [Related]
3. Identification and in silico characterization of a novel p.P208PfsX1 mutation in V-ATPase a3 subunit associated with autosomal recessive osteopetrosis in a Pakistani family.
Ajmal M; Mir A; Wahid S; Khor CC; Foo JN; Siddiqi S; Kauser M; Malik SA; Nasir M
BMC Med Genet; 2017 Dec; 18(1):148. PubMed ID: 29237407
[TBL] [Abstract][Full Text] [Related]
4. Effects of human a3 and a4 mutations that result in osteopetrosis and distal renal tubular acidosis on yeast V-ATPase expression and activity.
Ochotny N; Van Vliet A; Chan N; Yao Y; Morel M; Kartner N; von Schroeder HP; Heersche JN; Manolson MF
J Biol Chem; 2006 Sep; 281(36):26102-11. PubMed ID: 16840787
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of osteoclast bone resorption by disrupting vacuolar H+-ATPase a3-B2 subunit interaction.
Kartner N; Yao Y; Li K; Crasto GJ; Datti A; Manolson MF
J Biol Chem; 2010 Nov; 285(48):37476-90. PubMed ID: 20837476
[TBL] [Abstract][Full Text] [Related]
6. V-ATPase a3 isoform mutations identified in osteopetrosis patients abolish its expression and disrupt osteoclast function.
Matsumoto N; Matsukawa R; Takahashi S; Kudo K; Sun-Wada GH; Wada Y; Nakanishi-Matsui M
Exp Cell Res; 2020 Apr; 389(2):111901. PubMed ID: 32045577
[TBL] [Abstract][Full Text] [Related]
7. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.
Qin A; Cheng TS; Pavlos NJ; Lin Z; Dai KR; Zheng MH
Int J Biochem Cell Biol; 2012 Sep; 44(9):1422-35. PubMed ID: 22652318
[TBL] [Abstract][Full Text] [Related]
8. Disruption of the V-ATPase functionality as a way to uncouple bone formation and resorption - a novel target for treatment of osteoporosis.
Thudium CS; Jensen VK; Karsdal MA; Henriksen K
Curr Protein Pept Sci; 2012 Mar; 13(2):141-51. PubMed ID: 22044152
[TBL] [Abstract][Full Text] [Related]
9. Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis.
Xu J; Cheng T; Feng HT; Pavlos NJ; Zheng MH
Histol Histopathol; 2007 Apr; 22(4):443-54. PubMed ID: 17290355
[TBL] [Abstract][Full Text] [Related]
10. V-ATPases and osteoclasts: ambiguous future of V-ATPases inhibitors in osteoporosis.
Duan X; Yang S; Zhang L; Yang T
Theranostics; 2018; 8(19):5379-5399. PubMed ID: 30555553
[TBL] [Abstract][Full Text] [Related]
11. The V-ATPase a3 subunit mutation R740S is dominant negative and results in osteopetrosis in mice.
Ochotny N; Flenniken AM; Owen C; Voronov I; Zirngibl RA; Osborne LR; Henderson JE; Adamson SL; Rossant J; Manolson MF; Aubin JE
J Bone Miner Res; 2011 Jul; 26(7):1484-93. PubMed ID: 21305608
[TBL] [Abstract][Full Text] [Related]
12. A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.
Nyman JK; Väänänen HK
Calcif Tissue Int; 2010 Sep; 87(3):273-83. PubMed ID: 20596699
[TBL] [Abstract][Full Text] [Related]
13. V-ATPase a3 Subunit in Secretory Lysosome Trafficking in Osteoclasts.
Nakanishi-Matsui M; Matsumoto N
Biol Pharm Bull; 2022; 45(10):1426-1431. PubMed ID: 36184499
[TBL] [Abstract][Full Text] [Related]
14. Luteolin inhibition of V-ATPase a3-d2 interaction decreases osteoclast resorptive activity.
Crasto GJ; Kartner N; Yao Y; Li K; Bullock L; Datti A; Manolson MF
J Cell Biochem; 2013 Apr; 114(4):929-41. PubMed ID: 23129004
[TBL] [Abstract][Full Text] [Related]
15. The a3 isoform of the 100-kDa V-ATPase subunit is highly but differentially expressed in large (>or=10 nuclei) and small (Manolson MF; Yu H; Chen W; Yao Y; Li K; Lees RL; Heersche JN
J Biol Chem; 2003 Dec; 278(49):49271-8. PubMed ID: 14504271
[TBL] [Abstract][Full Text] [Related]
16. The R740S mutation in the V-ATPase a3 subunit results in osteoclast apoptosis and defective early-stage autophagy.
Ochotny N; Voronov I; Owen C; Aubin JE; Manolson MF
J Cell Biochem; 2013 Dec; 114(12):2823-33. PubMed ID: 23908015
[TBL] [Abstract][Full Text] [Related]
17. Osteopetrosis mutation R444L causes endoplasmic reticulum retention and misprocessing of vacuolar H+-ATPase a3 subunit.
Bhargava A; Voronov I; Wang Y; Glogauer M; Kartner N; Manolson MF
J Biol Chem; 2012 Aug; 287(32):26829-39. PubMed ID: 22685294
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic terminus of vacuolar type proton pump accessory subunit Ac45 is required for proper interaction with V(0) domain subunits and efficient osteoclastic bone resorption.
Feng H; Cheng T; Pavlos NJ; Yip KH; Carrello A; Seeber R; Eidne K; Zheng MH; Xu J
J Biol Chem; 2008 May; 283(19):13194-204. PubMed ID: 18227071
[TBL] [Abstract][Full Text] [Related]
19. The amino-terminal domain of the vacuolar proton-translocating ATPase a subunit controls targeting and in vivo dissociation, and the carboxyl-terminal domain affects coupling of proton transport and ATP hydrolysis.
Kawasaki-Nishi S; Bowers K; Nishi T; Forgac M; Stevens TH
J Biol Chem; 2001 Dec; 276(50):47411-20. PubMed ID: 11592965
[TBL] [Abstract][Full Text] [Related]
20. Diversity of proton pumps in osteoclasts: V-ATPase with a3 and d2 isoforms is a major form in osteoclasts.
Matsumoto N; Daido S; Sun-Wada GH; Wada Y; Futai M; Nakanishi-Matsui M
Biochim Biophys Acta; 2014 Jun; 1837(6):744-9. PubMed ID: 24561225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
